Trevi Therapeutics, Inc. (TRVI)
16.64
-0.18
(-1.10%)
USD |
NASDAQ |
Sep 09, 16:00
16.64
0.00 (0.00%)
After-Hours: 18:10
Trevi Therapeutics Enterprise Value : 2.077B for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 2.077B |
| September 04, 2026 | 2.140B |
| September 03, 2026 | 2.111B |
| September 02, 2026 | 2.110B |
| September 01, 2026 | 2.042B |
| August 31, 2026 | 2.046B |
| August 28, 2026 | 2.073B |
| August 27, 2026 | 2.240B |
| August 26, 2026 | 2.234B |
| August 25, 2026 | 2.238B |
| August 24, 2026 | 2.257B |
| August 21, 2026 | 2.240B |
| August 20, 2026 | 2.281B |
| August 19, 2026 | 2.361B |
| August 18, 2026 | 2.365B |
| August 17, 2026 | 2.314B |
| August 14, 2026 | 2.311B |
| August 13, 2026 | 2.267B |
| August 12, 2026 | 2.207B |
| August 11, 2026 | 2.217B |
| August 10, 2026 | 2.217B |
| August 07, 2026 | 2.318B |
| August 06, 2026 | 2.317B |
| August 05, 2026 | 2.338B |
| August 04, 2026 | 2.352B |
| Date | Value |
|---|---|
| August 03, 2026 | 2.231B |
| July 31, 2026 | 2.281B |
| July 30, 2026 | 2.302B |
| July 29, 2026 | 2.258B |
| July 28, 2026 | 2.307B |
| July 27, 2026 | 2.262B |
| July 24, 2026 | 2.179B |
| July 23, 2026 | 2.129B |
| July 22, 2026 | 2.154B |
| July 21, 2026 | 2.271B |
| July 20, 2026 | 2.070B |
| July 17, 2026 | 2.398B |
| July 16, 2026 | 2.154B |
| July 15, 2026 | 2.266B |
| July 14, 2026 | 2.232B |
| July 13, 2026 | 2.035B |
| July 10, 2026 | 2.223B |
| July 09, 2026 | 2.302B |
| July 08, 2026 | 2.329B |
| July 07, 2026 | 2.459B |
| July 06, 2026 | 2.238B |
| July 02, 2026 | 2.235B |
| July 01, 2026 | 2.190B |
| June 30, 2026 | 2.338B |
| June 29, 2026 | 2.221B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.848B |
| Corcept Therapeutics, Inc. | 12.00B |
| Veru, Inc. | 20.88M |
| Johnson & Johnson | 676.38B |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.80M |
| Total Expenses (Quarterly) | 17.80M |
| EPS Diluted (Quarterly) | -0.1136 |
| Earnings Yield | -2.06% |
| Normalized Earnings Yield | -2.060 |